Similar articles

• [Approval of a new nucleoside. Component of complete once daily regimen].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:91. MMW Fortschr Med. 2004. PMID: 15373067 German. No abstract available.
• Therapies. Confronting the limits of success.

  Cohen J. Cohen J. Science. 2002 Jun 28;296(5577):2320-4. doi: 10.1126/science.296.5577.2320. Science. 2002. PMID: 12089422 No abstract available.
• Factors associated with incomplete virological response to highly active antiretroviral therapy.

  Welch K, Morse A, Clark R, Ogbuokiri T. Welch K, et al. Clin Infect Dis. 2000 Feb;30(2):407-8. doi: 10.1086/313670. Clin Infect Dis. 2000. PMID: 10671360 No abstract available.
• Dynamics and evolution of HIV-1 during structured treatment interruptions.

  Frost SD. Frost SD. AIDS Rev. 2002 Jul-Sep;4(3):119-27. AIDS Rev. 2002. PMID: 12416446 Review.
• Impact of once- and twice-daily dosing regimens on adherence and overall safety.

  Hawkins T. Hawkins T. AIDS Read. 2004 Jun;14(6):320-2, 324, 329-31, 334-6. AIDS Read. 2004. PMID: 15243968 Review.